The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A pilot phase II multicenter study of nab-paclitaxel (Nab-P) and gemcitabine (G) as preoperative therapy for potentially resectable pancreatic cancer (PC).
Shawn MacKenzie
No relevant relationships to disclose
Herbert Zeh
Research Funding - Celgene
Laurence E. McCahill
No relevant relationships to disclose
Timothy D. Sielaff
No relevant relationships to disclose
Nathan Bahary
Research Funding - Celgene
Thomas Edward Gribbin
No relevant relationships to disclose
John E. Seng
No relevant relationships to disclose
Joseph W. Leach
No relevant relationships to disclose
Jocelyn Harmon
No relevant relationships to disclose
Michael J. Demeure
No relevant relationships to disclose
Daniel D. Von Hoff
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
A Jim Moser
No relevant relationships to disclose
Ramesh K. Ramanathan
Honoraria - Celgene
Research Funding - Celgene